CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Subscribe To Our Newsletter & Stay Updated
